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The development of stem cell-derived allogeneic therapeutics requires manufacturing processes able to 
generate high-density cultures of pluripotent stem cells (PSCs) to be further differentiated to target somatic cells. 
The Cell Plasticity platform of The Cell and Gene Therapy Catapult (CGT) is a core program that focuses on the 
cost efficient development of bioprocesses for the industrial manufacture of PSC-derived products in 2D and 3D 
culture systems. We started this program by establishing banks of PSCs adapted to defined culture systems 
and used conventional analytical techniques to characterise the cells to industry standards. Defined media were 
evaluated for the expansion of induced pluripotent stem cells (iPSC) in adherent culture. Scale-down high-
throughput tools along with Design of Experiment methodology have been employed to establish a baseline 
process for the expansion of PSC as cellular aggregates in stirred-suspension culture and targeting cell yield > 
5x106 viable cells/mL. We are currently investigating bioengineering parameters for scale-up and evaluating cell 
retention devices for the dissociation of PSC aggregates in a closed and automated fashion. In parallel, a 
framework of analytical assays comprising imaging, flow-cytometry and gene expression is under development 
for process monitor and control using a proprietary multi-parametric analysis approach.   
 
